UA84462C2 - Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой - Google Patents

Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой

Info

Publication number
UA84462C2
UA84462C2 UAA200611573A UAA200611573A UA84462C2 UA 84462 C2 UA84462 C2 UA 84462C2 UA A200611573 A UAA200611573 A UA A200611573A UA A200611573 A UAA200611573 A UA A200611573A UA 84462 C2 UA84462 C2 UA 84462C2
Authority
UA
Ukraine
Prior art keywords
imatinib
acid addition
methanesulfonic acid
addition salts
crystalline polymorphs
Prior art date
Application number
UAA200611573A
Other languages
English (en)
Ukrainian (uk)
Inventor
Войцех Щепек
Дорота Самсон-Лазинска
Богдан Загродзки
Магдалена Глице
Виолета Марушак
Катаржина Корчак
Ришард Модзелевски
Марта Лавецка
Лукаш Качмарек
Веслав Шелеевски
Уршула Фрачек
Петр Цмох
Original Assignee
Институт Фармацевтични
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL366885A external-priority patent/PL216883B1/pl
Application filed by Институт Фармацевтични filed Critical Институт Фармацевтични
Priority claimed from PL374074A external-priority patent/PL374074A1/pl
Publication of UA84462C2 publication Critical patent/UA84462C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
UAA200611573A 2004-04-02 2005-02-04 Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой UA84462C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL366885A PL216883B1 (pl) 2004-04-02 2004-04-02 Sposób wytwarzania krystalicznej formy a soli addycyjnej kwasu metanosulfonowego i 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-[(4-pirydyn-3-ylo)pirymidyn-2- -yloamino)fenylo]benzamidu
PL374074A PL374074A1 (pl) 2005-04-01 2005-04-01 Sposób wytwarzania krystalicznej formy Ó monomesylanu 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-[(4-pirydyn-3-ylo)pirymidyn-2-yloamino]fenylo]benzamidu
PCT/PL2005/000024 WO2005095379A2 (en) 2004-04-02 2005-04-02 Crystalline methanesulfonic acid addition salts of imatinib

Publications (1)

Publication Number Publication Date
UA84462C2 true UA84462C2 (ru) 2008-10-27

Family

ID=34981470

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611573A UA84462C2 (ru) 2004-04-02 2005-02-04 Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой

Country Status (5)

Country Link
US (1) US7732601B2 (ru)
EP (1) EP1742933A2 (ru)
IL (1) IL178097A (ru)
UA (1) UA84462C2 (ru)
WO (1) WO2005095379A2 (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
AR055613A1 (es) * 2005-08-26 2007-08-29 Novartis Ag Formas cristalinas delta y epsilon de mesilato de imatinib
KR20080078804A (ko) 2005-11-25 2008-08-28 노파르티스 아게 이마티니브 메실레이트의 ｆ, ｇ, ｈ, ｉ 및 ｋ 결정형
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
CA2651353C (en) 2006-04-27 2012-11-13 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form .alpha.
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008150481A2 (en) * 2007-05-29 2008-12-11 Sicor Inc. Processes for the preparation of crystalline form beta of imatinib mesylate
WO2009042803A1 (en) 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011100282A2 (en) * 2010-02-09 2011-08-18 Dr. Reddy's Laboratories Ltd. Imatinib mesylate polymorphs
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
US8609842B2 (en) 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
SI2582689T1 (sl) * 2010-06-18 2017-05-31 Krka, D.D., Novo Mesto Nova polimorfna oblika imatinib baze in priprava njenih soli
WO2012014000A1 (en) * 2010-07-30 2012-02-02 Ramesh Babu Potluri STABLE α-CRYSTAL FORM OF IMATINIB MESYLATE AND PREPARING PROCESS THEREOF
CN102146073A (zh) * 2011-02-23 2011-08-10 江苏先声药物研究有限公司 一种伊玛替尼甲烷磺酸盐α晶型新的制备方法
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
CN102321070B (zh) * 2011-07-27 2013-05-22 江苏先声药物研究有限公司 反溶剂重结晶法制备伊玛替尼甲烷磺酸盐α晶型
WO2013136141A1 (en) * 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
CN102617552A (zh) * 2012-04-06 2012-08-01 江南大学 一种制备α晶型甲磺酸伊马替尼的结晶方法
CN102633775B (zh) * 2012-04-06 2013-07-17 江南大学 一种甲磺酸伊马替尼α晶型的制备方法
CN103467446A (zh) * 2012-06-05 2013-12-25 广东东阳光药业有限公司 一种甲磺酸伊马替尼α晶型的制备方法
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
CN103570674A (zh) * 2012-08-04 2014-02-12 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
CN103058991A (zh) * 2012-12-28 2013-04-24 南京艾德凯腾生物医药有限责任公司 一种α晶型甲磺酸伊马替尼的制备方法
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process
CN103483314B (zh) * 2013-09-16 2015-02-18 南京优科生物医药研究有限公司 一种便捷的制备甲磺酸伊马替尼α晶型的方法
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
CN113260667B (zh) * 2018-12-21 2023-06-30 倍耐力轮胎股份公司 含硫化促进剂的胶囊，制备方法和在轮胎用弹性体胶料硫化中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060052387A1 (en) 2002-06-26 2006-03-09 Marsh Clay B Organic compounds

Also Published As

Publication number Publication date
US20070197545A1 (en) 2007-08-23
WO2005095379A3 (en) 2006-05-18
WO2005095379B1 (en) 2006-07-13
IL178097A0 (en) 2006-12-31
IL178097A (en) 2013-03-24
WO2005095379A2 (en) 2005-10-13
US7732601B2 (en) 2010-06-08
EP1742933A2 (en) 2007-01-17

Similar Documents

Publication Publication Date Title
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
CL2007002949A1 (es) Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora;
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
PE20051096A1 (es) Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2008059551A3 (en) Process for the preparation of imatinib and intermediates thereof
WO2013150545A8 (en) Process for preparation of benzimidazole derivatives and salts thereof
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
MX2010003849A (es) Antagonistas de cgrp.
RS51858B (en) 4 - [(3-FLUOROPHENOXY) PHENYLMETHYL] PIPERIDINE METANSULPHONATE: ITS USES, PROCESSING METHODS AND PHARMACEUTICAL COMPOSITIONS
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
NO20064114L (no) Fremgangsmate for fremstilling av N-arylpiperazinderivater
WO2006100026A8 (de) 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl-piperidine als cgrp-antagonisten
WO2006133904A3 (en) Methods and intermediates for the preparation of optionally radio-labeled imatinib
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
TW200613283A (en) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
EA200870045A1 (ru) СУЛЬФОКСИМИННЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ p38 MAP КИНАЗЫ
ATE411299T1 (de) Chlorsubstituierte guanidine
TW200732319A (en) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
ATE444964T1 (de) 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika